Inspire Biotherapeutics, a Toronto, Canada-based biotech company, raised an undisclosed amount in Pre-Seed funding.
Inspire’s Business Founders – C3i Center Inc, Octane Medical Group of Companies, and Ontario Institute for Regenerative Medicine – are providing investment, corporate development, and commercialization strategy.
The company intends to use the funds to accelerate its development efforts.
Founded by Dr. Bernard Thébaud and Dr. Sarah Wootton, Inspire is a biotech company with a mission to create life-saving gene therapies for monogenic and acquired diseases of the lung. Its lung tropic AAV gene therapy platform has demonstrated transduction and long-term expression in lung tissue without impact on other tissue types in disease-relevant animal models. The company is currently pursing initiation of a First-in-Human clinical trial for a lethal neonatal lung disease with short time to data readout and success of therapy. The platform can apply to cystic fibrosis, interstitial lung disease, pulmonary fibrosis, and other monogenic lung diseases.
FinSMEs
16/03/2023